
Opinion|Videos|August 9, 2024
Incorporating Patient Perspectives When Determining a Route of Administration for Biologic Therapies
Jill Zouzoulas, M.D., FACR, describes the best practices for incorporating patient perspectives when determining the ideal route of administration for those with rheumatologic diseases.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- How do you evaluate the costs between IV vs. subcutaneous therapies when deciding which route of administration to use in patients?
- Patient perspectives have been analyzed in those taking IV biologics for rheumatoid arthritis. What did the results show, and do they factor into your treatment decisions?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare Part D redesign reshapes market
2
Rural health is ailing. Is $50 billion enough to heal it?
3
A conversation with Tiffany Phung, Pharm.D., CSP, about how patient outcomes drive specialty pharmacy strategy
4
The sleep doctor who lives with a disorder he treats
5























